Kimberly-Clark Bets Over $40B on Kenvue Amid Tylenol Controversy -- Market Talk

Dow Jones

Nov 03

0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. (connor.hart@wsj.com)

(END) Dow Jones Newswires

November 03, 2025 07:28 ET (12:28 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2580229076"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580229076\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580229076?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580229076","market":"sh","top_or_hot":-1,"title":"Kimberly-Clark Bets Over $40B on Kenvue Amid Tylenol Controversy -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. (connor.hart@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 07:28 ET (12:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kimberly-Clark Bets Over $40B on Kenvue Amid Tylenol Controversy -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKimberly-Clark Bets Over $40B on Kenvue Amid Tylenol Controversy -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-03 20:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. (connor.hart@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 07:28 ET (12:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0128525929.USD","symbol_name":"TEMPLETON GLOBAL \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2580229076","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580229076","pubTimestamp":1762172880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","KVUE":"Kenvue Inc","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","BK4504":"桥水持仓","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","KMB":"金佰利","BK4183":"个人用品","BK4588":"碎股","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4018":"居家用品","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC"},"translate_title":"在泰诺争议中，金佰利(Kimberly-Clark)在Kenvue上押注超过40B美元——市场讨论","themeId":"d7f4f57ff2cf212a4a46fa1f7ed8723f","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KVUE":0.9,"KMB":1.5},"content_text":"0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. (connor.hart@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  November 03, 2025 07:28 ET (12:28 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}